Video

Dr. Krakow on Genetic Testing in Ovarian Cancer

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

In terms of genetic testing, Krakow states that if a patient has a family history, a first degree relative with ovarian cancer, or a personal history of either ovarian or breast cancer, they should be tested for the known high-risk genes. If a patient is Ashkenazi Jewish and is diagnosed with ovarian cancer, even without a known family history of breast or ovarian cancer, they should be tested.

Approximately, 1% to 2% of Ashkenazi Jewish women have the same mutation in BRCA1. What is interesting states Krakow, is that all populations report changes in BRCA1/2, so it is not unique to one population. However, it has been enriched in the Ashkenazi Jewish population, confirms Krakow.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD